Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · Real-Time Price · USD
0.3915
-0.0037 (-0.94%)
Jun 6, 2025, 1:46 PM - Market open

Company Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer.

Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer.

The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial.

It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015.

Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Leap Therapeutics, Inc.
Leap Therapeutics logo
Country United States
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 52
CEO Douglas Onsi

Contact Details

Address:
47 Thorndike Street, Suite B1-1
Cambridge, Massachusetts 02141
United States
Phone 617 714 0360
Website leaptx.com

Stock Details

Ticker Symbol LPTX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001509745
CUSIP Number 52187K101
ISIN Number US52187K2006
Employer ID 27-4412575
SIC Code 2834

Key Executives

Name Position
Douglas E. Onsi J.D. Chief Financial Officer, General Counsel, Treasurer and Secretary, President, Chief Executive Officer & Director
Augustine J. Lawlor Chief Operating Officer
Dr. Cynthia A. Sirard M.D. Chief Medical Officer
Dr. Jason S. Baum Ph.D. Chief Scientific Officer
Mark O'Mahony Chief Manufacturing Officer
Christine M. Granfield Vice President and Head of Regulatory Affairs and Quality

Latest SEC Filings

Date Type Title
May 13, 2025 10-Q Quarterly Report
May 13, 2025 8-K Current Report
Apr 28, 2025 ARS Filing
Apr 28, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2025 DEF 14A Other definitive proxy statements
Mar 26, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 26, 2025 10-K Annual Report
Mar 26, 2025 8-K Current Report
Mar 17, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing